Cargando…
Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570235/ https://www.ncbi.nlm.nih.gov/pubmed/33067318 http://dx.doi.org/10.1136/jitc-2020-001114 |
_version_ | 1783596902184386560 |
---|---|
author | Wang, Michael Jain, Preetesh Chi, T Linda Chen, Sheree E Heimberger, Amy Weathers, Shiao-Pei Zheng, Lianqing Rao, Arati V Rossi, John M |
author_facet | Wang, Michael Jain, Preetesh Chi, T Linda Chen, Sheree E Heimberger, Amy Weathers, Shiao-Pei Zheng, Lianqing Rao, Arati V Rossi, John M |
author_sort | Wang, Michael |
collection | PubMed |
description | Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity. |
format | Online Article Text |
id | pubmed-7570235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-75702352020-10-21 Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 Wang, Michael Jain, Preetesh Chi, T Linda Chen, Sheree E Heimberger, Amy Weathers, Shiao-Pei Zheng, Lianqing Rao, Arati V Rossi, John M J Immunother Cancer Case Report Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity. BMJ Publishing Group 2020-10-16 /pmc/articles/PMC7570235/ /pubmed/33067318 http://dx.doi.org/10.1136/jitc-2020-001114 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Case Report Wang, Michael Jain, Preetesh Chi, T Linda Chen, Sheree E Heimberger, Amy Weathers, Shiao-Pei Zheng, Lianqing Rao, Arati V Rossi, John M Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title_full | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title_fullStr | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title_full_unstemmed | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title_short | Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2 |
title_sort | management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor t-cell therapy in zuma-2 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570235/ https://www.ncbi.nlm.nih.gov/pubmed/33067318 http://dx.doi.org/10.1136/jitc-2020-001114 |
work_keys_str_mv | AT wangmichael managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT jainpreetesh managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT chitlinda managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT chenshereee managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT heimbergeramy managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT weathersshiaopei managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT zhenglianqing managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT raoarativ managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 AT rossijohnm managementofapatientwithmantlecelllymphomawhodevelopedsevereneurotoxicityafterchimericantigenreceptortcelltherapyinzuma2 |